Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 1998

View Archived Issues

Company Profile: ZymeTx

Batimastat enhances antitumor activity of cisplatin against ovarian cancer

Postmarketing evaluation of Clozaril may lead to increased patient availability

Biovector licenses DNA delivery technology from NIH

Matrix proceeds with full enrollment for IntraDose phase II trials

Antiherpes agent will enter phase II, Abbott says

Safety and pharmacokinetic data reported for MEDI-507

Company Profile: IGT Pharma

Phytera signs R&D and marketing agreement with NeuroSearch

Rivastigmine ameliorates immediate and long-term sequelae of closed-head injury

Gilead: Q1 1998 highlights

Interneuron: Q2 1998 highlights

Helopharm describes improved class III antiarrhythmic agents

Oral antiinflammatory/analgesic compounds with reduced ulcerogenic potential

Neuroprotective heterocyclic compounds developed at Cambridge NeuroScience

IL-8 receptor antagonists described by SKB

Glaxo Wellcome introduces anti-HIV combination product in U.K.

Somatostatin analogue launched in U.K.

New PDE IV inhibitors from Euroceltique

Spotlight on treatment and prevention of C. difficile infection

Phase I toxicity and efficacy results for CT-2584 presented at ASCO meeting

Cytokine suppressants: an effective approach to the treatment of cancer cachexia

Cor's fibrinogen antagonist on the way to market

Leuvectin proceeds to phase II for renal cell carcinoma

Neurocrine Biosciences initiates clinical-stage development of IL-4 fusion toxin

C225 + radiotherapy produces 100% response rate in head and neck cancer

Helicase-primase, an enzyme target for the design of new antiviral agents